Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter 2-Week Pilot Study to Evaluate the Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) Given Orally in Female Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs DNK 333 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Novartis
- 12 Jul 2008 New trial record.